本帖最后由 老马 于 2012-1-13 21:20 编辑
^8 ?( A; ` @
% v5 [' t) T8 o+ V( L3 V1 C爱必妥和阿瓦斯丁的比较$ }3 S( R8 C$ p/ M2 N3 ?
. g# ^, W% g1 l" s5 w
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" F. c7 X2 `. `7 {1 j
0 w; f: D1 @9 T
3 `3 t- c) @! K. n
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( y* t1 O* P, w8 L
==================================================
( U1 G5 A! F3 j. j" m6 r4 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 t% c3 J+ k& R9 h! HPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 R0 l+ X/ {9 @; RResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 T- ?) w, P7 F' U9 n& j0 L
|